COMMUNIQUÉS West-GlobeNewswire

Marker Therapeutics Highlights Expanded Manufacturing Support of CDMO Partner Following Formation of Kincellis Advanced Therapies
22/09/2026
HOUSTON, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company developing multi-antigen recognizing (MAR)-T cell therapies for the treatment of hematologic [...]
Filana Therapeutics Announces FDA Lift of Clinical Hold on Simufilam, Enabling Phase 2a Study in TSC-Related Epilepsy
22/09/2026
Patient screening for the Phase 2a study is expected to begin by the first quarter of 2027 Filana has engaged a leading clinical research organization, has identified clinical trial sites, and is recruiting potential [...]
Adagene Announces NMPA Clearance of Investigational New Drug Application for ADG138, a Novel HER2xCD3 Double-Masked Bispecific T-Cell Engager
22/09/2026
Phase 1 study with ADG138 for patients with advanced solid tumors is expected to begin in China in the fourth quarter of 2026 ADG138 is a double-masked T-cell engager, applying Adagene’s proprietary SAFEbody® precision [...]
Medera Expands Singapore Presence Through Partnership with National Heart Centre Singapore
22/09/2026
Medera establishes Singapore laboratory and office to support human mini-heart cardiac disease modeling, drug discovery, and regional cardiovascular clinical innovation BOSTON and SINGAPORE, Sept. 22, 2026 (GLOBE [...]
Adventist Health Bakersfield Introduces Kern County’s First Next Generation Robotic-Assisted Bronchoscopy
22/09/2026
Advanced technology helps physicians detect lung cancer earlier and improve treatment BAKERSFIELD, Calif., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Kern County and surrounding areas now have access to a next-generation, [...]
Envisagenics and Boehringer Ingelheim Enter Multi-Target Collaboration to Develop First-in-Class Precision Therapies Based on RNA Splicing-Derived Targets for Hard-to-Treat Cancers
22/09/2026
Envisagenics’ AI-powered SpliceCore ® platform opens up alternative RNA splicing – one of the last largely untapped sources of tumor-specific targets – for precision oncology Boehringer Ingelheim may apply selected [...]
Clene to Present at Upcoming Investor Conferences
22/09/2026
SALT LAKE CITY, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) today announced that management will participate at the 5 th Annual ROTH Healthcare Opportunities Conference and at the Lytham Partners [...]
SCYNEXIS Appoints Seasoned Industry Veteran Steven K. Burke, M.D., to its Board of Directors
22/09/2026
New director brings nephrology development expertise and over 30 years of experience in the biopharmaceutical industry JERSEY CITY, N.J., Sept. 22, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX) (“SCYNEXIS” or [...]
Natural design. Amplified: Smith+Nephew announces FDA 510(k) clearance and first surgical cases of LANDMARK™ Total Knee System
22/09/2026
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) and has completed the first surgical cases with [...]
Novo and UNICEF expand partnership to support a healthier start for more than 80 million children
22/09/2026
The four-year expansion will focus on childhood overweight and obesity prevention for over 80 million children across seven priority countries: Mexico, Colombia, Indonesia, the Philippines, India, Egypt and Kenya Novo [...]
Reviva to Participate in the Lytham Partners Fall 2026 Investor Conference
22/09/2026
The Company invites individual and institutional investors, as well as advisors and analysts with an interest in the life sciences sector, to attend the corporate presentation at https://lythampartners.com/fall2026/ [...]
PDS Biotech Announces Publication of VERSATILE-002 Phase 2 Clinical Trial Results of PDS0101 with pembrolizumab in HPV16-Positive Recurrent and/or Metastatic (R/M) Head and Neck Cancer in JAMA Oncology
22/09/2026
39.3 months median overall survival in first-line (1L) R/M immune checkpoint inhibitor naïve patients Company continues to prioritize PDS0301 in metastatic colorectal cancer (mCRC) while pursuing partnership strategy [...]
Recludix Pharma to Present at the Oppenheimer Private Life Sciences Company Showcase
22/09/2026
SAN DIEGO, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Recludix Pharma, a clinical-stage company leading the discovery and development of inhibitors of challenging targets for inflammatory disease, today announced that Nancy [...]
IMUNON Reports Independent Data Monitoring Committee Recommends Continued Phase 2 Development of IMNN-001 Following Favorable Safety Review
22/09/2026
Independent Data Monitoring Committee recommends the ongoing Phase 2 MRD study continue without modification following its review of all safety data to date No cytokine release syndrome, systemic toxicities or serious [...]
SCIENTURE Expands Commercial Reach of REZENOPY™ to Addiction Treatment Centers through an Agreement with a Distribution Partner
22/09/2026
Agreement provides dedicated commercial channel for REZENOPY ™ across approximately 2,000 OTP (Opioid Treatment Program) Clinics and other Addiction Treatment Center Networks in the United States According to IQVIA data [...]
Eos SENOLYTIX to Highlight Next-Generation Mitochondria-Targeted Therapeutics at 17th World Congress on Targeting Mitochondria
22/09/2026
Founder and CEO Kevin Slawin, M.D., to deliver industry keynote on advancing mitochondrial-targeted geropeptide medicine Eos advancing lead candidate MitoXcel™ geropeptide PTC-2105 toward first-in-human studies for [...]
Aprea Therapeutics to Present Updated Interim Phase 1 Data on WEE1 Inhibitor APR-1051 in an Oral Presentation at 38th EORTC-NCI-AACR Symposium
22/09/2026
DOYLESTOWN, Pa., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery and development of [...]
Elevar Therapeutics Receives FDA Conditional Acceptance of LYRFIGTU as Brand Name for Lirafugratinib
22/09/2026
In March, the FDA granted Priority Review of Lyrfigtu (lirafugratinib); PDUFA date of September 25, 2026 Lyrfigtu (lirafugratinib) achieved a 46% ORR, in CCA patients with FGFR2 fusion or other rearrangement Fort Lee, N [...]
Vistagen Announces Preliminary Positive Data from Open-Label Extension Portion of PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder
22/09/2026
Fasedienol nasal spray was well-tolerated in patients with social anxiety disorder with no new drug-related safety findings after as-needed use for up to 12 months Clinically relevant improvement in social anxiety over [...]

Pages